Q1 Earnings Forecast for SERA Issued By William Blair

Sera Prognostics, Inc. (NASDAQ:SERA - Free Report) - Analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of Sera Prognostics in a research note issued to investors on Thursday, May 8th. William Blair analyst A. Brackmann forecasts that the company will post earnings per share of ($0.23) for the quarter. The consensus estimate for Sera Prognostics' current full-year earnings is ($0.96) per share. William Blair also issued estimates for Sera Prognostics' Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.23) EPS and FY2026 earnings at ($0.92) EPS.

Sera Prognostics Trading Down 0.8%

SERA stock traded down $0.02 during trading on Monday, hitting $2.37. 36,637 shares of the stock traded hands, compared to its average volume of 118,184. The stock has a market cap of $89.26 million, a price-to-earnings ratio of -2.39 and a beta of 0.99. Sera Prognostics has a one year low of $2.10 and a one year high of $9.91. The company has a 50 day simple moving average of $3.33 and a 200 day simple moving average of $5.39.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.04. The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.06 million.

Institutional Trading of Sera Prognostics

Several hedge funds have recently modified their holdings of the company. Jane Street Group LLC grew its position in Sera Prognostics by 24.8% during the 3rd quarter. Jane Street Group LLC now owns 14,225 shares of the company's stock worth $111,000 after acquiring an additional 2,826 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in Sera Prognostics in the fourth quarter worth $28,000. Rhumbline Advisers grew its holdings in shares of Sera Prognostics by 10.6% during the fourth quarter. Rhumbline Advisers now owns 36,101 shares of the company's stock worth $294,000 after purchasing an additional 3,468 shares during the last quarter. Sanders Morris Harris LLC increased its stake in shares of Sera Prognostics by 4.0% in the first quarter. Sanders Morris Harris LLC now owns 94,200 shares of the company's stock valued at $347,000 after buying an additional 3,600 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Sera Prognostics by 5.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 81,228 shares of the company's stock valued at $661,000 after buying an additional 4,115 shares during the last quarter. Institutional investors and hedge funds own 54.64% of the company's stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.